| Today's News |
|---|
45 minutes ago.
 |
Michigan State University's $12 million purchase of Press building will
MLive.com - MI,USA
MLive.com Long term, MSU needs more space for medical research and research in related fields, Rappley said. "It's a pretty broad set of disciplines that come together to study health problems," she said. Whether MSU would tear down the 173840-square [more]
 |
| |
|
45 minutes ago.
|
Texas Scottish Rite Hospital for Children Announces New Leadership Roles
MarketWatch - USA
Daniel "Dan" J. Sucato, MD, MS, TSRHC orthopaedic surgeon and Director of the Sarah M. and Charles E. Seay/Martha and Pat Beard Center for Excellence in Spine Research, is named Chief of Staff and will lead the hospital's medical team. [more]
|
| Last 10 Articles (Prior to Today)
|
Friday, January 27
|
MedCity News - Cleveland,OH,USA
Medical device company nContact, a developer of products to treat arrhythmias, has raised close to half a million dollars. The Morrisville, North Carolina company secured a total of $433761 in debt financing from one investor, according to securities [more]
|
Friday, January 27
|
Medical News Today - UK
The US FDA has approved Inlyta (axitinib) for the treatment of advanced renal cell carcinoma, a type of kidney cancer, in patients with whom other drugs have not been effective, the FDA (Food and Drug Administration) announced today. [more]
|
Friday, January 27
|
Zacks.com - Chicago,IL,USA
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has received a confirmation that the US Food and Drug Administration (“FDA”) had cleared the Alere Influenza A&B Test f [more]
|
Friday, January 27
|
Bridgeton News - Bridgeton,NJ,USA
“This should be done with the oversight of local elected officials, community stakeholders, union and workforce representatives, and trusted members of the medical community under the guidance of the Attorney General to ensure there are no ... [more]
|
Friday, January 27
|
MarketWatch - USA
MarketWatch (press release) About BYDUREON(TM) (exenatide extended-release for injectable suspension) BYDUREON, previously known as exenatide once weekly, is the first and only once-weekly medicine to be approved by the FDA for the treatment of type [more]
|
Friday, January 27
|
Reuters - NY,USA
US patients rarely use cytokines, such as interferon, and are far more likely to be given Sutent as an initial treatment, the FDA has said. Most FDA advisers said the medicine was not a significant advance over other treatments. [more]
|
Friday, January 27
|
Plastics Today
Delrin SC699 polyacetal was specifically developed for parts requiring precision molding in the healthcare industry and is compliant with regulations from the US Food and Drug Adminsitration (FDA) and European Union. A new control grade of acetal is [more]
|
Friday, January 27
|
Wall Street Journal - USA
Based in Cambridge, Mass., Verastem is an early-stage company working to develop cancer treatments that target cancer stem cells, along with diagnostic tests. The scientific co-founders of the company, researchers at the Whitehead Institute. develope [more]
|
Friday, January 27
|
PR Newswire (press release) - USA
PR Newswire (press release) 27, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately-held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announce [more]
|
Friday, January 27
|
Huffington Post - New York,NY,USA
Researchers led by Dr. George A. Bray of the Pennington Biomedical Research Center in Baton Rouge, Louisiana, conducted a study to determine whether a person's level of dietary protein independently affects body composition, weight gain or energy ... [more]
|
